Alzheimer's Disease Trial, Recruiting NCT06099587 Sponsor: Rennes University Hospital Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT06099587
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 50 and 80 years old
  • French is your first/native language
  • You are right-handed
  • You have completed at least a primary school level of education
  • You do not have any medical or mental health conditions that could affect your memory or thinking, apart from the conditions this trial is studying (see next point)
  • You have been diagnosed with either "subjective cognitive decline" (where you feel your memory has gotten worse but tests appear normal) or "mild cognitive impairment" linked to early Alzheimer's disease (where some memory or thinking changes can be measured on tests) (confirm with trial site)
  • You are covered by a French social security scheme
  • You have been fully informed about the trial and have signed a consent form agreeing to take part

Who may not be able to join:

  • You have a condition or device in your body that makes having an MRI scan unsafe, such as a pacemaker, cochlear implant, certain metal implants, recent joint replacements or bone devices, or you experience severe claustrophobia (fear of enclosed spaces)
  • You have a hearing or vision problem that would interfere with the tests used in the trial
  • You are currently pregnant or breastfeeding
  • You are under any form of legal protection or guardianship, or are currently deprived of your liberty
  • You have a score above 2 on a specific medical scale used to assess blood flow-related brain changes (confirm with trial site)
  • You have been diagnosed with dementia

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Pierre-Yves JONIN, PhD, Rennes University Hospital

Phone: 299284321

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Rennes University Hospital
Registry
ClinicalTrials.gov
Start date
2 July 2024
Est. completion
3 July 2028

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Diffusion-MRI based parameters estimates of medial temporal lobe gray matter microstructure

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov